Research output: Contribution to journal › Review article › peer-review
Topological aspects of the design of nanocarriers for therapeutic peptides and proteins. / Knauer, Nadezhda; Pashkina, Ekaterina; Apartsin, Evgeny.
In: Pharmaceutics, Vol. 11, No. 2, 91, 21.02.2019.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Topological aspects of the design of nanocarriers for therapeutic peptides and proteins
AU - Knauer, Nadezhda
AU - Pashkina, Ekaterina
AU - Apartsin, Evgeny
PY - 2019/2/21
Y1 - 2019/2/21
N2 - Supramolecular chemistry holds great potential for the design of versatile and safe carriers for therapeutic proteins and peptides. Nanocarriers can be designed to meet specific criteria for given application (exact drug, administration route, target tissue, etc.). However, alterations in the topology of formulation components can drastically change their activity. This is why the supramolecular topology of therapeutic nanoconstructions has to be considered. Herein, we discuss several topological groups used for the design of nanoformulations for peptide and protein delivery: modification of polypeptide chains by host-guest interactions; packaging of proteins and peptides into liposomes; complexation and conjugation with dendrimers. Each topological type has its own advantages and disadvantages, so careful design of nanoformulations is needed. Ideally, each case where nanomedicine is needed requires a therapeutic construction specially created for that taking into account features of the administration route, target tissue, or organ, properties of a drug, its bioavailability, etc. The wide number of studies in the field of protein delivery by supramolecular and nanocarriers for proteins and peptides evidence their increasing potential for different aspects of the innovative medicine. Although significant progress has been achieved in the field, there are several remaining challenges to be overcome in future.
AB - Supramolecular chemistry holds great potential for the design of versatile and safe carriers for therapeutic proteins and peptides. Nanocarriers can be designed to meet specific criteria for given application (exact drug, administration route, target tissue, etc.). However, alterations in the topology of formulation components can drastically change their activity. This is why the supramolecular topology of therapeutic nanoconstructions has to be considered. Herein, we discuss several topological groups used for the design of nanoformulations for peptide and protein delivery: modification of polypeptide chains by host-guest interactions; packaging of proteins and peptides into liposomes; complexation and conjugation with dendrimers. Each topological type has its own advantages and disadvantages, so careful design of nanoformulations is needed. Ideally, each case where nanomedicine is needed requires a therapeutic construction specially created for that taking into account features of the administration route, target tissue, or organ, properties of a drug, its bioavailability, etc. The wide number of studies in the field of protein delivery by supramolecular and nanocarriers for proteins and peptides evidence their increasing potential for different aspects of the innovative medicine. Although significant progress has been achieved in the field, there are several remaining challenges to be overcome in future.
KW - Carriers
KW - Cavitands
KW - Dendrimers
KW - Formulations
KW - Liposomes
KW - Nanomedicine
KW - Peptides
KW - Proteins
KW - PERIODIC PROPERTY PATTERNS
KW - SALMON-CALCITONIN
KW - DRUG-DELIVERY
KW - SYSTEMATIC FRAMEWORK
KW - peptides
KW - formulations
KW - proteins
KW - AMINO-ACIDS
KW - cavitands
KW - LIPOSOMES
KW - BRAIN DELIVERY
KW - dendrimers
KW - liposomes
KW - nanomedicine
KW - carriers
KW - INSULIN
KW - HYDROXYPROPYL-BETA-CYCLODEXTRIN
KW - TARGETED DELIVERY
UR - http://www.scopus.com/inward/record.url?scp=85063470295&partnerID=8YFLogxK
U2 - 10.3390/pharmaceutics11020091
DO - 10.3390/pharmaceutics11020091
M3 - Review article
C2 - 30795556
AN - SCOPUS:85063470295
VL - 11
JO - Pharmaceutics
JF - Pharmaceutics
SN - 1999-4923
IS - 2
M1 - 91
ER -
ID: 19039271